Immune Checkpoint Inhibitors ‘High-Risk Yet Promising’ for Cancer Patients Who Undergo Organ Transplant

A meta-analysis led by a researcher at Roswell Park Comprehensive Cancer Center has identified key factors that could improve outcomes for cancer patients treated with immune checkpoint inhibitors (ICIs) before or after a solid-organ transplant.

By
May 30, 2025
4 min

Roswell Park Comprehensive Cancer Center

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Roswell Park Comprehensive Cancer Center

Buffalo, NY
Key Differentiators
- Oncology
- Hematology
- Transplant Immunology
#2

Massachusetts General Hospital Cancer Center

Boston, MA
Key Differentiators
- Oncology
- Immunotherapy
- Transplant Medicine
#3

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, MD
Key Differentiators
- Oncology
- Immunotherapy
- Transplant Immunology
#4

University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

San Francisco, CA
Key Differentiators
- Oncology
- Immunotherapy
- Transplant Medicine

Immune Checkpoint Inhibitors ‘High-Risk Yet Promising’ for Cancer Patients Who Undergo Organ Transplant

Top Institutions in Oncology

Roswell Park Comprehensive Cancer Center

Massachusetts General Hospital Cancer Center

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

Original Source(s)

Immune Checkpoint Inhibitors ‘High-Risk Yet Promising’ for Cancer Patients Who Undergo Organ Transplant

Related Content

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer